Topic: multiple sclerosis
Pear Therapeutics and Novartis’ new digital treatment is designed to be given alongside a disease-modifying therapy for relapsing multiple sclerosis.
Maryland researchers discovered a type of stem cell in hair follicles that can rebuild the myelin that breaks down in brain diseases like multiple sclerosis.
The resubmission comes one year after Celgene was rocked by a refusal-to-file notice from the FDA.
The submission comes a year after Celgene received an embarrassing refuse-to-file letter for ozanimod from the FDA.
Scientists from CUNY and the Icahn School of Medicine have identified a possible mechanism of action for Biogen's MS drug Tecfidera.
The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials.
A University of Chicago teams has shown that a derivative of hypertension drug Wytensin can protect myelin in animal models of multiple sclerosis.
Researchers at the University of Toronto and UCSF point to the gut as the source of immune cells that mitigate brain inflammation in MS.
Sanofi laid out $125 million to take a stake in two of Denali's RIPK1 inhibitors, and now one will be tested in three tough-to-treat brain disorders.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.